Log in to search using one of your social media accounts:


Is 'miracle' cancer therapy all it's cracked up to be?

Nigel Lewis-Baker, 71, from Effingham in Surrey, was told he had just months to live three years ago after being diagnosed with prostate cancer.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news

Related Links:

Personalization of prostate cancer therapy through phosphoproteomics, Published online: 11 May 2018; doi:10.1038/s41585-018-0014-0Yang and colleagues discuss the clinical need and rationale for a phosphoproteomics approach to personalizing prostate cancer treatment. They describe current technologies, clinical findings, and challenges and strategies to realizing routine clinical application of phosphoproteomics.
Source: Nature Reviews Urology - Category: Urology & Nephrology Authors: Source Type: research
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.8b00152
Source: Molecular Pharmaceutics - Category: Drugs & Pharmacology Authors: Source Type: research
In conclusion, we identify montelukast may be used as a novel agent for the treatment of prostate cancer by decreasing HIF-1α protein translation. PMID: 29708817 [PubMed - as supplied by publisher]
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research
In this study, PEGylated bilirubin-based nanoparticles (BRNPs) were chosen as an appropriate delivery carrier because of their ability to release drugs in response to TME-associated reactive oxygen species (ROS) through rapid particle disruption. As a model SMDC, ACUPA-SN38 was synthesized by linking the prostate membrane-specific antigen (PSMA)-targeting ligand, ACUPA, to the chemotherapeutic agent, SN38. ACUPA-SN38 was loaded into BRNPs using a film-formation and rehydration method. The resulting ACUPA-SN38@BRNPs exhibited ROS-mediated particle disruption and rapid release of the SMDC, resulting in greater cytotoxicity t...
Source: Biomacromolecules - Category: Biochemistry Authors: Tags: Biomacromolecules Source Type: research
This study focused to clarify the roles of Metadherin (MTDH) and miR-342-3p in prostate cancer. We identified that MTDH was up-regulated and miR-342-3p was down-regulated in the prostate tissues, and there is an inverse correlation between MTDH and miR-342-3p. Functional studies revealed that miR-342-3p directly targets MTDH via binding to the 3’untranslated regions (UTRs) in the prostate cancer cells. Moreover, we also found MTDH overexpression in DU145 and PC3 cells inhibited apoptosis. Subsequently, miR-342-3p has been revealed to reverse the MTDH effect on the cellular apoptosis in the further studies. Our result...
Source: Saudi Journal of Biological Sciences - Category: Biology Source Type: research
Abstract The current paradigm in the development of new cancer therapies is the ability to target tumor cells while avoiding harm to noncancerous cells. Furthermore, there is a need to develop novel therapeutic options against drug-resistant cancer cells. Herein, we characterized the placental-derived stem cell (PLSC) exosomes (PLSCExo) and evaluated their anti-cancer efficacy in prostate cancer (PCa) cell lines. Nanoparticle tracking analyses revealed the size distribution (average size 131.4 ± 0.9 nm) and concentration of exosomes (5.23 × 1010±1.99 × 109 per ml) secreted b...
Source: Biochemical and Biophysical Research communications - Category: Biochemistry Authors: Tags: Biochem Biophys Res Commun Source Type: research
Conclusion: This study demonstrated that PSMA-11–derived dual-labeled dye conjugates are feasible for providing PSMA-specific pre-, intra-, and postoperative detection of prostate cancer lesions and have high potential for future clinical translation.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Basic Source Type: research
The ETS Related Gene (ERG) is dormant and non-detectable in normal prostate. Despite of significant advancements in prostate cancer treatment in recent years, hormone therapy remains the main treatment for advanced CaP. Unfortunately, late stage prostate cancers are highly prone to treatment resistance. Thus, there is an urgent need to develop effective and novel inhibitors to target CaP driver genes in the early stages of prostate tumorigenesis. ERG oncoprotein and ERG dependent pathways are promising targets for early stage cancer therapy.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Prostate Cancer: Advanced (including  Drug Therapy) IV Source Type: research
To isolate cell-specific internalizing aptamers (Apt) against prostate cancer cells and evaluating their efficiency in vitro and in vivo. Engineering aptamer-targeted nanoparticles for prostate cancer therapy.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Prostate Cancer: Basic Research & Pathophysiology III Source Type: research
We examined the anticancer effects of NCL1 and NCD38, selective inhibitors of LSD1 (LSD1i) that were first discovered at our university.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Prostate Cancer: Basic Research & Pathophysiology I Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Health | Prostate Cancer